Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Death within 1 month of diagnosis in childhood cancer: an analysis of risk factors and scope of the problem (Green A et al. J Clin Oncol, March 2017)

J Clin Oncol, March 2017 
Green A et al

Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib (Shima H et al. Pediatr Blood Cancer, February 2017)

Pediatr Blood Cancer, February 2017
Shima H et al.  


Abstract

Bone marrow samples of newly diagnosed children with chronic-phase chronic myeloid leukemia (CML) were obtained at diagnosis and after imatinib initiation and stained with anti-human CD34, CD38, CD123, CD45RA, cMpl, and lineage antibodies. Flow cytometric analysis revealed that granulocyte macrophage progenitor predominance in CML progenitors at diagnosis and elevated cMpl expression in bone marrow progenitors at 3 months may predict poor outcome in children with chronic-phase CML treated with imatinib. We recommend flow cytometric analysis of bone marrow in the early phase of treatment, as it is a convenient tool that may predict treatment response and guide CML management.

 


© 2017 Wiley Periodicals, Inc.

Optimal management for pediatric chronic myeloid leukemia (Tanzizawe A. Pediatrics International, March 2016)

Pediatrics International, March 2016 
Akihiko Tanzizawa

Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukemia with bone marrow fibrosis (Hussein K et al. Leukemia, February 2017)

Leukemia, February 2017
Hussein K et al.  


Abstract

Pediatric chronic myeloid leukemia (ped-CML) is rare and ped-CML with fibre accumulation in the bone marrow (MF) is thought to be even rarer. In adults (ad-CML), fibrosis represents an adverse prognostic factor. So far, the pro-fibrotic changes in the bone marrow microenvironment have not been investigated in detail in ped-CML. From a total of 66 ped-CML in chronic phase, biopsies were analysable and 10 had MF1/2 (MF1, n=8/10; MF2, n=2/10). We randomly selected 16 ped-CML and 16 ad-CML cases with and without fibrosis (each n=8) as well as 18 non-neoplastic controls. Bone marrow samples were analysed with a real-time PCR-based assay (including 127 genes for pediatric cases) and by immunohistochemistry. We found increased expression of megakaryocytic genes in ped-CML. The number of megakaryocytes and pro-platelets are increased in CML patients but the most significant increase was noted for ped-CML-MF1/2. Anti-fibrotic MMP9 expression was lower in children than in adults. Cell mobilisation-related CXCL12 was decreased in young and adult patients with CML but not the corresponding receptor CXCR4. In summary, fibre accumulation in ped-CML-MF1/2 is associated with increased megakaryocytic proliferation and increased interstitial pro-platelet deposition. Deregulated expression of matrix modulating factors shifts the bone marrow microenvironment towards fibrosis.

 

 

 

 

Early response does not predict outcome in children and adolescents with chronic myeloid leukemia treated with high-dose imatinib (Giona F et al. Br J Haematol, Dec 2016)

Br J Haematol, December 2016
Giona F. et al

 

Link to full paper 

  1. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy (Proschmann R et al. Haematologica, November 2016)
  2. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America (Karalexi MA et al. Eur J Cancer, Sept 2016)
  3. Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database (Wang Y et al. Oncotarget, Aug 2016)
  4. Pediatric chronic myeloid leukemia with inv(3) (q21q26.2) and T lymphoblastic transformation: a case report (Lewen M et al. Biomark Res, July 2016)